The United States represents a significant market for human rabies immunoglobulin due to its well-established healthcare infrastructure, widespread availability of post-exposure prophylaxis treatments, and strong public health surveillance systems. Although human rabies cases remain relatively rare in the country, healthcare providers maintain strict protocols for managing potential rabies...